Austria

Austria

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.76 (0.61 - 0.91) 2019 Modelled IHME
0.76 (0.62 - 0.89) 2018 Modelled IHME
0.76 (0.62 - 0.90) 2017 Modelled IHME
0.78 (0.64 - 0.91) 2016 Modelled IHME
0.8 (0.64 - 0.94) 2015 Modelled IHME
0.81 (0.66 - 0.95) 2014 Modelled IHME
0.82 (0.67 - 0.95) 2013 Modelled IHME
0.82 (0.68 - 0.95) 2012 Modelled IHME
0.83 (0.69 - 0.96) 2011 Modelled IHME
0.83 (0.69 - 0.97) 2010 Modelled IHME
0.84 (0.70 - 0.97) 2009 Modelled IHME
0.85 (0.71 - 0.99) 2008 Modelled IHME
0.87 (0.71 - 1) 2007 Modelled IHME
0.88 (0.72 - 1.02) 2006 Modelled IHME
0.89 (0.72 - 1.04) 2005 Modelled IHME
0.89 (0.73 - 1.04) 2004 Modelled IHME
0.9 (0.74 - 1.06) 2003 Modelled IHME
0.9 (0.75 - 1.07) 2002 Modelled IHME
0.91 (0.75 - 1.09) 2001 Modelled IHME
0.92 (0.75 - 1.10) 2000 Modelled IHME
0.92 (0.76 - 1.10) 1999 Modelled IHME
0.93 (0.75 - 1.11) 1998 Modelled IHME
0.93 (0.76 - 1.11) 1997 Modelled IHME
0.94 (0.76 - 1.11) 1996 Modelled IHME
0.94 (0.76 - 1.12) 1995 Modelled IHME
0.95 (0.77 - 1.12) 1994 Modelled IHME
0.95 (0.77 - 1.12) 1993 Modelled IHME
0.95 (0.77 - 1.12) 1992 Modelled IHME
0.96 (0.78 - 1.13) 1991 Modelled IHME
0.96 (0.77 - 1.14) 1990 Modelled IHME
1.03 (0.51 - 1.89) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.06 (0.04 - 0.08) 2019 Modelled IHME
0.06 (0.04 - 0.08) 2018 Modelled IHME
0.05 (0.04 - 0.07) 2017 Modelled IHME
0.05 (0.03 - 0.06) 2016 Modelled IHME
0.04 (0.03 - 0.06) 2015 Modelled IHME
0.05 (0.03 - 0.06) 2014 Modelled IHME
0.05 (0.03 - 0.07) 2013 Modelled IHME
0.06 (0.04 - 0.08) 2012 Modelled IHME
0.07 (0.04 - 0.09) 2011 Modelled IHME
0.07 (0.04 - 0.10) 2010 Modelled IHME
0.07 (0.04 - 0.10) 2009 Modelled IHME
0.07 (0.05 - 0.10) 2008 Modelled IHME
0.08 (0.05 - 0.10) 2007 Modelled IHME
0.08 (0.05 - 0.10) 2006 Modelled IHME
0.08 (0.05 - 0.11) 2005 Modelled IHME
0.1 (0.06 - 0.12) 2004 Modelled IHME
0.13 (0.08 - 0.17) 2003 Modelled IHME
0.17 (0.10 - 0.23) 2002 Modelled IHME
0.21 (0.13 - 0.29) 2001 Modelled IHME
0.25 (0.15 - 0.35) 2000 Modelled IHME
0.29 (0.18 - 0.40) 1999 Modelled IHME
0.33 (0.21 - 0.46) 1998 Modelled IHME
0.37 (0.24 - 0.52) 1997 Modelled IHME
0.4 (0.27 - 0.57) 1996 Modelled IHME
0.42 (0.28 - 0.60) 1995 Modelled IHME
0.42 (0.28 - 0.59) 1994 Modelled IHME
0.42 (0.28 - 0.59) 1993 Modelled IHME
0.42 (0.28 - 0.59) 1992 Modelled IHME
0.42 (0.28 - 0.59) 1991 Modelled IHME
0.42 (0.28 - 0.59) 1990 Modelled IHME
0.32 (0.15 - 0.62) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
6 (4 - 9) 2019 Modelled IHME
6 (4 - 9) 2018 Modelled IHME
6 (4 - 9) 2017 Modelled IHME
6 (4 - 9) 2016 Modelled IHME
6 (4 - 9) 2015 Modelled IHME
6 (4 - 9) 2014 Modelled IHME
6 (4 - 9) 2013 Modelled IHME
6 (4 - 9) 2012 Modelled IHME
6 (4 - 10) 2011 Modelled IHME
7 (4 - 10) 2010 Modelled IHME
7 (4 - 10) 2009 Modelled IHME
7 (4 - 10) 2008 Modelled IHME
7 (5 - 10) 2007 Modelled IHME
7 (5 - 10) 2006 Modelled IHME
7 (5 - 10) 2005 Modelled IHME
7 (5 - 10) 2004 Modelled IHME
7 (5 - 10) 2003 Modelled IHME
7 (5 - 10) 2002 Modelled IHME
7 (5 - 11) 2001 Modelled IHME
7 (5 - 11) 2000 Modelled IHME
7 (5 - 11) 1999 Modelled IHME
7 (5 - 11) 1998 Modelled IHME
7 (5 - 11) 1997 Modelled IHME
7 (5 - 11) 1996 Modelled IHME
7 (5 - 11) 1995 Modelled IHME
7 (5 - 11) 1994 Modelled IHME
7 (5 - 11) 1993 Modelled IHME
7 (5 - 11) 1992 Modelled IHME
7 (5 - 11) 1991 Modelled IHME
7 (5 - 11) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
85 2018 Survey/reported WHO/UNICEF
90 2017 Survey/reported WHO/UNICEF
87 2016 Survey/reported WHO/UNICEF
93 2015 Survey/reported WHO/UNICEF
98 2014 Survey/reported WHO/UNICEF
95 2013 Survey/reported WHO/UNICEF
92 2012 Survey/reported WHO/UNICEF
89 2011 Survey/reported WHO/UNICEF
86 2010 Survey/reported WHO/UNICEF
83 2009 Survey/reported WHO/UNICEF
83 2008 Survey/reported WHO/UNICEF
85 2007 Survey/reported WHO/UNICEF
83 2006 Survey/reported WHO/UNICEF
86 2005 Survey/reported WHO/UNICEF
83 2004 Survey/reported WHO/UNICEF
83 2003 Survey/reported WHO/UNICEF
81 2002 Survey/reported WHO/UNICEF
44 2001 Survey/reported WHO/UNICEF
33 2000 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
321 (244 - 468) 2015 Survey/reported EMCDDA, 2017

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
50 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HBV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Some (11-30%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.93 (0.76 - 1.13) 2019 Modelled IHME
0.92 (0.76 - 1.12) 2018 Modelled IHME
0.92 (0.75 - 1.12) 2017 Modelled IHME
0.91 (0.75 - 1.11) 2016 Modelled IHME
0.91 (0.74 - 1.12) 2015 Modelled IHME
0.91 (0.74 - 1.12) 2014 Modelled IHME
0.91 (0.75 - 1.12) 2013 Modelled IHME
0.91 (0.75 - 1.12) 2012 Modelled IHME
0.92 (0.76 - 1.12) 2011 Modelled IHME
0.92 (0.76 - 1.13) 2010 Modelled IHME
0.92 (0.76 - 1.12) 2009 Modelled IHME
0.92 (0.76 - 1.12) 2008 Modelled IHME
0.92 (0.76 - 1.11) 2007 Modelled IHME
0.92 (0.75 - 1.10) 2006 Modelled IHME
0.92 (0.75 - 1.10) 2005 Modelled IHME
0.91 (0.75 - 1.10) 2004 Modelled IHME
0.91 (0.75 - 1.10) 2003 Modelled IHME
0.91 (0.75 - 1.09) 2002 Modelled IHME
0.91 (0.75 - 1.09) 2001 Modelled IHME
0.91 (0.74 - 1.10) 2000 Modelled IHME
0.91 (0.74 - 1.09) 1999 Modelled IHME
0.9 (0.74 - 1.09) 1998 Modelled IHME
0.9 (0.74 - 1.08) 1997 Modelled IHME
0.9 (0.74 - 1.08) 1996 Modelled IHME
0.9 (0.74 - 1.08) 1995 Modelled IHME
0.9 (0.74 - 1.07) 1994 Modelled IHME
0.89 (0.74 - 1.07) 1993 Modelled IHME
0.89 (0.74 - 1.08) 1992 Modelled IHME
0.89 (0.73 - 1.08) 1991 Modelled IHME
0.89 (0.73 - 1.08) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
0.5 (0.10 - 0.70) 2014 Modelled Gower et al, 2014
People who inject drugs (PWID)
Download
Value (%) Year Type Source
31.3 (18.70 - 46.30) 2013 Survey/reported EMCDDA
60.9 (54.80 - 67) 2012 Modelled Degenhardt L et al, 2017
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
32 (23 - 42) 2019 Modelled IHME
32 (24 - 42) 2018 Modelled IHME
32 (23 - 42) 2017 Modelled IHME
32 (23 - 41) 2016 Modelled IHME
32 (23 - 41) 2015 Modelled IHME
32 (23 - 41) 2014 Modelled IHME
32 (23 - 41) 2013 Modelled IHME
32 (23 - 41) 2012 Modelled IHME
32 (23 - 41) 2011 Modelled IHME
32 (24 - 41) 2010 Modelled IHME
32 (24 - 41) 2009 Modelled IHME
32 (24 - 41) 2008 Modelled IHME
32 (24 - 41) 2007 Modelled IHME
32 (24 - 42) 2006 Modelled IHME
32 (24 - 42) 2005 Modelled IHME
32 (24 - 41) 2004 Modelled IHME
32 (24 - 41) 2003 Modelled IHME
32 (24 - 41) 2002 Modelled IHME
31 (23 - 40) 2001 Modelled IHME
31 (23 - 40) 2000 Modelled IHME
31 (23 - 40) 1999 Modelled IHME
31 (23 - 39) 1998 Modelled IHME
31 (23 - 39) 1997 Modelled IHME
30 (22 - 39) 1996 Modelled IHME
31 (22 - 39) 1995 Modelled IHME
31 (22 - 39) 1994 Modelled IHME
31 (22 - 39) 1993 Modelled IHME
31 (23 - 40) 1992 Modelled IHME
31 (23 - 40) 1991 Modelled IHME
31 (23 - 41) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (244 - 468) 2015 Survey/reported EMCDDA, 2017

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
50 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HBV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Some (11-30%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.76 (%)
2019
(0.61 - 0.91(%))
IHME
HCV (RNA/cAg+)
0.93 (%)
2019
(0.76 - 1.13(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
167
2019
(124 - 218)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
558
2019
(433 - 690)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.06 (%)
2019, latest modelled
(0.04 - 0.08(%))
IHME

Prevalence PWID

HCV
31.30 (%)
2013, survey/surveillance
(18.70 - 46.30(%))
EMCDDA

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV
321
2015
(244 - 468)
EMCDDA, 2017
Eligible for HBV generic medicines
Eligible for HCV generic medicines